Plant-Derived and Endogenous Cannabinoids in Epilepsy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical drug investigation

• Publication date

  2016-02-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s40261-016-0379-xPMID 26892745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cannabinoids for paediatric epilepsy: Weeding out the issues

  2015cited by this paper
• Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

  2015cited by this paper
• Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy

  2015cited by this paper
• Phytocannabinoids and epilepsy

  2015cited by this paper
• Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.

  2015cited by this paper
• Cannabinoids in the Treatment of Epilepsy.

  2015cited by this paper
• Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs.

  2015cited by this paper
• Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.

  2014cited by this paper
• Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting.

  2014cited by this paper
• Cannabinoids for epilepsy.

  2014cited by this paper
• Endocannabinoids, Related Compounds and Their Metabolic Routes

  2014cited by this paper
• Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

  2014cited by this paper
• Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

  2013cited by this paper
• Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.

  2013cited by this paper
• Metabolism of endocannabinoids and related N‐acylethanolamines: Canonical and alternative pathways

  2013cited by this paper
• CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations.

  2013cited by this paper
• Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology

  2012cited by this paper
• Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12)[S]

  2012cited by this paper
• Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.

  2011cited by this paper
• Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways

  2011cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

  2010cited by this paper
• N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA).

  2010cited by this paper
• Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy

  2010cited by this paper
• Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

  2009cited by this paper
• cDNA cloning and characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-acyltransferases.

  2009cited by this paper
• Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.

  2009cited by this paper
• Selective CB2 Receptor Agonism Protects Central Neurons from Remote Axotomy-Induced Apoptosis through the PI3K/Akt Pathway

  2009cited by this paper
• Anandamide Biosynthesis Catalyzed by the Phosphodiesterase GDE1 and Detection of Glycerophospho-N-acyl Ethanolamine Precursors in Mouse Brain*

  2008cited by this paper
• Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage

  2007cited by this paper
• Endocannabinoids block status epilepticus in cultured hippocampal neurons.

  2007cited by this paper
• Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy.

  2007cited by this paper
• Allosterism and cannabinoid CB(1) receptors: the shape of things to come.

  2007cited by this paper
• Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature.

  2007cited by this paper
• A biosynthetic pathway for anandamide

  2006cited by this paper
• The endocannabinoid system controls key epileptogenic circuits in the hippocampus.

  2006cited by this paper
• A Second Fatty Acid Amide Hydrolase with Variable Distribution among Placental Mammals*

  2006cited by this paper
• Endocannabinoid Biosynthesis Proceeding through Glycerophospho-N-acyl Ethanolamine and a Role for α/β-Hydrolase 4 in This Pathway*

  2006cited by this paper
• Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.

  2006cited by this paper
• Cannabinoids in medicine: A review of their therapeutic potential.

  2006cited by this paper
• Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase*

  2005cited by this paper
• Medical use of cannabis in the Netherlands

  2005cited by this paper
• Toward drugs derived from cannabis

  2004cited by this paper
• Medicinal cannabis: rational guidelines for dosing.

  2004cited by this paper
• Marijuana on the state

  2004cited by this paper
• Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners*

  2004cited by this paper
• Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies.

  2004cited by this paper
• Marijuana use and epilepsy

  2004cited by this paper
• Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

  2003cited by this paper
• Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase

  2003cited by this paper
• CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

  2003cited by this paper
• The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy

  2003cited by this paper
• Brain monoglyceride lipase participating in endocannabinoid inactivation

  2002cited by this paper
• Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor.

  2002cited by this paper
• Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

  2002cited by this paper
• Therapeutic aspects of cannabis and cannabinoids

  2001cited by this paper
• Marijuana: federal smoke clears, a little.

  2001cited by this paper
• Alcohol and Marijuana: Effects on Epilepsy and Use by Patients with Epilepsy

  2001cited by this paper
• Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

  2001cited by this paper
• Medicinal marijuana: a comprehensive review.

  1998cited by this paper
• Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

  1996cited by this paper
• Marihuana: The Forbidden Medicine

  1993cited by this paper
• Double-blind clinical study of cannabidiol as a secondary anticonvulsant

  1990cited by this paper
• Illicit drug use and the risk of new-onset seizures.

  1990cited by this paper
• N-acylated glycerophospholipids and their derivatives.

  1990cited by this paper
• Complex partial seizure symptoms affected by marijuana abuse.

  1990cited by this paper
• Anticonvulsant effect of cannabidiol.

  1986cited by this paper
• Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

  1980cited by this paper
• Letter: Marihuana use among epileptics.

  1976cited by this paper
• Marihuana Use Among Epileptics

  1976cited by this paper
• Anticonvulsant activity of four oxygenated cannabidiol derivatives.

  1975cited by this paper
• Anticonvulsant nature of marihuana smoking.

  1975cited by this paper
• Grand mal convulsions subsequent to marijuana use. Case report.

  1967cited by this paper
• Grand mal convulsions subsequent to marijuana use. Case report.

  1967cited by this paper
• On the Preparations of the Indian Hemp, or gunjah*

  1843cited by this paper

• Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease.

  2023cites this paper
• Cannabis use in the United States and its impact on gastrointestinal health.

  2023cites this paper
• Current and promising therapeutic options for Dravet syndrome

  2022cites this paper
• Juvenile cannabidiol chronic treatments produce robust changes in metabolic markers in adult male Wistar rats.

  2021cites this paper
• Sleep-wake cycle disturbances and NeuN-altered expression in adult rats after cannabidiol treatments during adolescence

  2021cites this paper
• Cannabis Use for Therapeutic Purposes by Children and Youth at a Tertiary Teaching Hospital in Canada: A Retrospective Chart Review.

  2020cites this paper
• Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review.

  2020cites this paper
• Cannabidiol Treatment for Refractory Epilepsies in Pediatrics

  2020cites this paper
• Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.

  2019cites this paper
• "Cannabis and cannabinoids" therapeutic applications and safety: a literature review

  2019cites this paper
• Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice

  2019cites this paper
• Nature's Medicines to Treat Epileptic Seizures

  2018cites this paper
• Medical Marijuana: Just the Beginning of a Long, Strange Trip?

  2017cites this paper
• Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.

  2017cites this paper
• Cannabidiol provides viable treatment opportunity formultipleneurological pathologies of autism spectrum disorder

  2017cites this paper
• Cannabidiol provides viable treatment opportunity formultipleneurological pathologies of autism spectrum disorder

  2017cites this paper
• Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

  2017cites this paper
• Reply to ‘Hitting two birds with one stone: daily scheduled opiods in preventing migraine and migraine‐related epilepsy (migralepsy)’

  2016cites this paper
• Managing drug-resistant epilepsy: challenges and solutions

  2016cites this paper